SCHEMBL29993829

SCHEMBL29993829

FC(F)(F)c1cnc(Cl)nc1-c1c[nH]c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 15/20 0.54
▸ CCNH P51946 15/20 0.54
▸ MNAT1 P51948 13/20 0.54
▸ CCNE1 P24864 12/20 0.54
▸ CDK2 P24941 12/20 0.54
▸ CCNK O75909 12/20 0.54
▸ CDK12 Q9NYV4 12/20 0.54
▸ CCNT1 O60563 11/20 0.54
▸ CDK9 P50750 11/20 0.54
▸ CDK5 Q00535 1/20 0.50
▸ CDK5R1 Q15078 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517413 1.00 CDK7 (0.54) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL21026876 0.84 CDK5 (0.69) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL24839369 0.84 CDK7 (0.55) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL24900503 0.84 CCNK (0.48) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL30957595 0.84 CCNK (0.48) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL30957590 0.84 TDO2 (0.47) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL24900493 0.84 TDO2 (0.47) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL21629046 0.83 CCNK (0.44) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL21178668 0.83 CLK1 (0.50) CDK7CCNHMNAT1CCNE1CDK2
SCHEMBL21184587 0.83 CCNK (0.42) CDK7CCNHMNAT1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118159533-A Heterocyclic compounds and their use 艾森医药有限公司 2024-06-07 — — CN disclosed
WO-2023040998-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2023-03-23 — — WO disclosed
CN-108276382-B Cyclin-dependent kinase inhibitor and application thereof 南京圣和药物研发有限公司 2022-10-18 — — CN disclosed
Send feedback